# Surufatinib or Surufatinib Combined With Vinorelbine for Non-Small Cell Lung Cancer

> **NCT04922658** · PHASE2 · UNKNOWN · sponsor: **Affiliated Cancer Hospital & Institute of Guangzhou Medical University** · enrollment: 60 (estimated)

## Conditions studied

- Advanced Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Surufatinib
- **DRUG:** Surufatinib Plus Vinorelbine

## Key facts

- **NCT ID:** NCT04922658
- **Lead sponsor:** Affiliated Cancer Hospital & Institute of Guangzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-07-01
- **Primary completion:** 2024-12
- **Final completion:** 2025-06
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04922658

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04922658, "Surufatinib or Surufatinib Combined With Vinorelbine for Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04922658. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*